Ferrer Internacional Initiates Phase III Clinical Studies for Novel Antibacterial Compound, Ozenoxacin, in Development as a Topical Treatment for Impetigo and Other Infectious Dermatological Conditions
1/19/2012 10:27:03 AM
More...
|
CepTor Corporation (CEPO.OB) Executes LOI With Ferring For Late Stage Product; Superoxide Dismutase Targeted For Phase 2B Clinical Trials
9/15/2006 9:57:37 AM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) To Sell Global Biologics Manufacturing Business For $80 Million To Ferring Holding SA; Major Milestone Achieved In Savient's New Strategic Direction
10/19/2005 5:13:06 PM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) Enters Co-Promotion Agreement With Ferring Pharmaceuticals, Inc. For Nuflexxa; Savient To Establish Sales Force Targeting Rheumatologists Upon Sale Of Global Biologics Manufacturing Business
10/19/2005 5:13:06 PM
More...
|
Savient Pharmaceuticals, Inc. (SVNT) Provides Update On Closing Of Sale Of Global Biologics Manufacturing Business To Ferring B.V.
10/19/2005 5:09:21 PM
More...
|